Rapid prototyping and validation of FS-FBMC dynamic spectrum radio with simulink and ZynqSDR

This paper presents the research carried out in developing and targeting a novel real-time Dynamic Spectrum Access (DSA) Frequency Spread Filter Bank Multicarrier (FS-FBMC) transmitter prototype to programmable ‘ZynqSDR’ Software Defined Radio (SDR) hardware, and introduces a series of experiments used to validate the design’s ‘cognitive’ DSA capabilities. This transmitter is a proof of concept, that uses DSA techniques to enable Secondary Users (SUs) to access the band traditionally used for FM Radio broadcasting (88-108 MHz), and establish data communication channels in vacant parts of the FM Radio Primary User (PU) spectrum using a multicarrier modulation scheme with a Non Contiguous (NC) channel mask. Once implemented on the hardware, the transmitter is subjected to various FM Radio environments sampled from around Central Scotland, and it is demonstrated that it can dynamically adapt its NC transmitter mask in real time to protect the FM Radio signals it detects. A video is presented of this dynamic on-hardware spectral reconfiguration, and the reader is encouraged to view the video to appreciate the responsiveness of the design. An investigation into potential FBMC guardband sizes is carried out, with initial findings indicating a guardband of 200 kHz (either side of an FM Radio station) is required in order to prevent interference with the PUs. This paper also demonstrates the capabilities of the MATLAB®/ Simulink ZynqSDR workflow, and provides a case study and reference design that we feel other researchers working in this field can benefit from

Design and management of an orthopaedic bone bank in the Netherlands

The design and management of an orthopaedic bone bank is a complex process in which medical organisation and legislation intertwine. Neither in the Netherlands, nor in any other European country, there are official guidelines for the organisation and management of an orthopaedic bone bank. In the Netherlands, the recently modified ‘law of security and quality for using human materials’ (WVKL) dictates requirements for technical and organisational aspects for the use of human tissue and cells. The bone bank procedures include a thorough questionnaire for donor selection, extensive serological, bacteriological and histopathological examination, as well as standard procedures for registration, processing, preservation, storage and distribution of bone allografts. This article describes the organisation of an accredited bone bank and can be used as a proposition for an official guideline or can be useful as an example for other orthopaedic bone banks in Europe

Successful treatment of tracheal stenosis by rigid bronchoscopy and topical mitomycin C: a case report

Tracheal stenosis is a known complication of prolonged intubation. It is difficult to treat and traditional surgical approach is associated with significant risk and complications. Recurrent stenosis due to granulation tissue necessitates repeated procedures. We describe a case of short web-like tracheal stenosis (concentric membranous stenosis less than 1 cm in length without associated cartilage damage) managed by a minimally invasive thoracic endoscopic approach. Topical application of Mitomycin C, a potent fibroblast inhibitor reduces granulation tissue formation and prevents recurrence

Keratin 12 missense mutation induces the unfolded protein response and apoptosis in meesmann epithelial corneal dystrophy

Meesmann epithelial corneal dystrophy (MECD) is a rare autosomal dominant disorder caused by dominant-negative mutations within the KRT3 or KRT12 genes, which encode the cytoskeletal protein keratins K3 and K12, respectively. To investigate the pathomechanism of this disease, we generated and phenotypically characterized a novel knock-in humanized mouse model carrying the severe, MECD-associated, K12-Leu132Pro mutation. Although no overt changes in corneal opacity were detected by slit-lamp examination, the corneas of homozygous mutant mice exhibited histological and ultrastructural epithelial cell fragility phenotypes. An altered keratin expression profile was observed in the cornea of mutant mice, confirmed by western blot, RNA-seq and quantitative real-time polymerase chain reaction. Mass spectrometry (MS) and immunohistochemistry demonstrated a similarly altered keratin profile in corneal tissue from a K12-Leu132Pro MECD patient. The K12-Leu132Pro mutation results in cytoplasmic keratin aggregates. RNA-seq analysis revealed increased chaperone gene expression, and apoptotic unfolded protein response (UPR) markers, CHOP and Caspase 12, were also increased in the MECD mice. Corneal epithelial cell apoptosis was increased 17-fold in the mutant cornea, compared with the wild-type (P < 0.001). This elevation of UPR marker expression was also observed in the human MECD cornea. This is the first reporting of a mouse model for MECD that recapitulates the human disease and is a valuable resource in understanding the pathomechanism of the disease. Although the most severe phenotype is observed in the homozygous mice, this model will still provide a test-bed for therapies not only for corneal dystrophies but also for other keratinopathies caused by similar mutations

Mifamurtide for the treatment of nonmetastatic osteosarcoma

International audienceINTRODUCTION: The standard treatment for osteosarcoma requires both macroscopic surgical wide resection and postoperative multi-drug chemotherapy in neoadjuvant and adjuvant settings. However, the 5-year event-free survival has remained at a plateau of 60-70% of patients with nonmetastatic osteosarcoma for more than 30 years. AREAS COVERED: Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine; L-MTP-PE) is a new agent. L-MTP-PE is a nonspecific immunomodulator, which is a synthetic analog of a component of bacterial cell walls. L-MTP-PE activates macrophages and monocytes as a potent activator of immune response in addition to standard chemotherapy. It also improves the overall survival from 70 to 78% and results in a one-third reduction in the risk of death from osteosarcoma. This review summarizes the most recent findings about L-MTP-PE and its therapeutic application for nonmetastatic osteosarcoma. EXPERT OPINION: Recently, L-MTP-PE has been approved in Europe for the treatment of nonmetastatic osteosarcoma with chemotherapy. L-MTP-PE in combination with traditional treatment is expected to go mainstream and to be beneficial for patients with osteosarcoma. Information about potential benefit regarding mifamurtide use in the neoadjuvant setting (i.e., before surgery) and/or usefulness of L-MTP-PE in metastatic in relapsed and metastatic osteosarcoma requires analysis of expanded access and/or future clinical trials of L-MTP-PE in high-burden and low-burden situations

Two become one : the integration of male and female labour markets in the English and Welsh coalfields

Two become one: the integration of male and female labour markets in the English and Welsh Coalfields, Regional Studies. This paper explores the extent to which the labour markets for men and women are becoming integrated as a single entity. It does so in the specific context of the English and Welsh coalfields, where major job losses in the coal industry fell almost exclusively on men. Using data from 1981 to 2008, the paper presents ‘labour market accounts’ for the coalfields that reveal changing female labour force participation and employment, and it compares these trends with those among men in the same places. Evidence emerges of two relatively independent labour markets – male and female – operating in the 1980s in the same geographic space. However, over time a degree of integration appears to have occurred. As a result, women increasingly have to compete with men for the same jobs and a greater proportion of new job opportunities in the former coalfields are now going to men